Hospitals that serve a high volume of low-income and uninsured patients rely on Disproportionate Share Hospital (DSH) funding to maintain ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

On April 28, AEI’s Kirsten Axelsen hosted the former North Carolina Department of Health and Human Services Secretary Kody Kinsley; Anthony DiGiorgio of the University of California, San Francisco; ...

If HHS’ 340B rebate model pilot proceeds as planned, more than 2,700 U.S. hospitals will collectively be saddled with approximately $400 million in operational costs and 11.2 million labor burden ...

It has been 30 years since the 340B drug pricing program became law. 340B is one of a series of policies that those of us serving in Congress at the time adopted to address the need for a robust ...

For three decades, the 340B drug pricing program has helped hospitals that serve high numbers of low-income patients offer and expand a range of important programs and services that advance health ...

It is with great interest that I read Representative Henry Waxman’s defense of the 340B program recently published in Health Affairs Forefront. As a physician dedicated to serving vulnerable ...

In a letter last week, Johnson & Johnson informed certain hospitals of a major change it plans to make in the way it gives out discounts on two drugs. The company has found itself in opposition to ...

Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform. Its criticisms ...